Hogan Lovells has advised Jennewein Biotechnologie GmbH on its capital increase.
The capital increase was executed with the participation of existing investors.
Jennewein Biotechnologie is a science-based company in the field of industrial biotechnology and is specialized in the development of new production processes for scarce functional sugars. Human milk oligosaccharides (HMOs) represent one of the Company’s major fields of activity. These are complex sugar molecules that, in nature, are found uniquely in human milk.
Hogan Lovells Team for Jennewein Biotechnologie GmbH included Prof. Dr. Michael Schlitt (Picture – Partner, Lead), Peter Huber (Partner), Dr. Susanne Ries (Of Counsel), Mark Devlin (Counsel), Dr. Timo Lockemann, Christian Schröder, Kilian Pfahl (Associates) (all Corporate); Eva-Christina Sommer (Business Lawyer), Andreas Mildner (Research Assistant) (all Capital Markets).
Involved fees earner: Mark Devlin – Hogan Lovells; Peter Huber – Hogan Lovells; Timo Lockemann – Hogan Lovells; Kilian Pfahl – Hogan Lovells; Susanne Ries – Hogan Lovells; Michael Schlitt – Hogan Lovells; Christian Schröder – Hogan Lovells; Eva-Christina Sommer – Hogan Lovells;
Law Firms: Hogan Lovells;
Clients: Jennewein Biotechnologie GmbH;